Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Funding to advance AI-native drug R&D engine and pipelines, including MDR-001, an oral GLP-1 small-molecule in Phase III clinical trials in China.
-
ALPHARETTA, Ga., July 09, 2026 (GLOBE NEWSWIRE) -- Heald, a digital metabolic health platform, today announced that consumers who purchase a Dexcom Stelo or Abbott Lingo continuous glucose monitor...
-
Austin, TX, USA, July 03, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Antidiabetic Drugs Market Size, Trends, and Insights By Drug Class (Insulin,...
-
- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech’s CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows ...
-
Applied Biologics completes translational study showing XWRAP® exhibits favorable wound-healing biology vs. conventional placental tissue processing.
-
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
-
Growing role of machine learning, deep learning and predictive analytics in addressing clinical, operational and economic challenges in kidney care.
-
Austin, TX, USA, June 17, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “GLP-1 Receptor Agonist Market Size, Trends and Insights By Product Type...
-
FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT
-
La FDA approuve le Tzield de Sanofi comme première thérapie modificatrice pour enfants 8-17 ans atteints de diabète type 1 stade 3, retardant le déclin ins